This company has been marked as potentially delisted and may not be actively trading. NYSE:ARA American Renal Associates (ARA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About American Renal Associates Stock (NYSE:ARA) 30 days 90 days 365 days Advanced Chart Get ARA alerts:Sign Up Key Stats Today's Range$11.33▼$11.5250-Day Range$11.46▼$11.5252-Week Range$5.57▼$11.98Volume9,831 shsAverage Volume106,940 shsMarket Capitalization$397.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Read More… Receive ARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter. Email Address ARA Stock News HeadlinesBayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of CardiologyAugust 31, 2023 | benzinga.comAnemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateFebruary 22, 2023 | finance.yahoo.comRevealed: Steve Jobs' Secret Project Comes to Life on July 21st?Did Steve Jobs Leave Behind a $25 Trillion Gift for America? In his final years, America's greatest innovator worked on a secretive project beyond Apple's walls— a vision he believed would transform our nation's economy and restore its global leadership. Insiders called it "extraordinary" and "a model for improving America." On July 21st, this hidden legacy could finally be revealed, unlocking what CNBC calls a "$25 trillion opportunity" for generations to come.June 22, 2025 | InvestorPlace (Ad)Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)January 11, 2023 | finance.yahoo.comContinuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives DemandJanuary 2, 2023 | finance.yahoo.comDalian Atkinson: Footballer killed hours before renal treatmentOctober 7, 2022 | bbc.comARA Appoints James Myers Vice President, Program Innovation and GrowthJune 22, 2022 | finance.yahoo.comAmerican Renal Associates Holdings, Inc. NewsJune 20, 2022 | thestreet.comSee More Headlines ARA Stock Analysis - Frequently Asked Questions How were American Renal Associates' earnings last quarter? American Renal Associates Holdings, Inc. (NYSE:ARA) announced its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.09. The business earned $209.69 million during the quarter, compared to analyst estimates of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%. When did American Renal Associates IPO? American Renal Associates (ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers. What other stocks do shareholders of American Renal Associates own? Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Gilead Sciences (GILD), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings11/11/2020Today6/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNYSE:ARA CIK1498068 Webwww.americanrenal.com Phone978-922-3080FaxN/AEmployees4,977Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.79 million Net Margins-2.04% Pretax MarginN/A Return on Equity-3.56% Return on Assets-0.24% Debt Debt-to-Equity Ratio7.54 Current Ratio1.05 Quick Ratio1.02 Sales & Book Value Annual Sales$822.52 million Price / Sales0.48 Cash Flow$1.69 per share Price / Cash Flow6.80 Book Value$2.59 per share Price / Book4.45Miscellaneous Outstanding Shares34,543,000Free FloatN/AMarket Cap$397.94 million OptionableOptionable Beta1.11 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:ARA) was last updated on 6/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored379 passengers walked away from thisForget OpenAI, ChatGPT, and the $2 trillion chip race… The real story is buried inside a new U.S. patent. E...True Market Insiders | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding American Renal Associates Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share American Renal Associates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.